2 These data underline the importance of high-throughput screening to find ligands at GPCRs as therapeutic leads both for well-known receptors and for orphan receptors. Dopamine receptors are involved in disorders like Parkinson's disease or schizophrenia and therefore represent important targets for these diseases. 3 Two classes of human dopamine receptors can be distinguished: G s coupled D1-like receptors (hD1 and hD5 receptors), and G coupled D2-like receptors (hD2, hD3, and hD4 receptors). 4 Even though dopaminergic agonists and antagonists with a certain subtype selectivity are available, 5 their therapeutic use is limited because of severe side effects -for instance, extrapyramidal motor effects of haloperidol and phenothiazines, or severe side effects of clozapine. [6] [7] [8] The therapeutic long-term benefit and adverse drug reactions of new atypical neuroleptics like ziprasidone still need further evaluation. 9 Therefore, the synthesis of novel ligands without therapy-limiting side effects, better subtype selectivity and specificity, and subsequent screening of compound libraries are still under thorough investigation in the dopaminergic field. So far, high-throughput radioligand binding methods as well as some nonradioactive screening systems (eg, fluorescence polarization) have been established. 10 However, what is needed are simple and robust screening systems that can be performed in laboratories with "low to medium" throughput and avoid the use of radioisotopes. Further, these screening methods should allow a simple functional discrimination between agonists and antagonists and be ideally applicable to a majority of receptors. Therefore, a functional screening method for GPCRs was recently developed based on the increase in intracellular Ca 11 Ca 2+ is a near universal signal for not only ion channels but also recombinantly expressed GPCRs. 12 The functional Ca 2+ assay allows screening at various G s , G, Gq, and Go coupled receptors, among them the recombinantly expressed human dopamine receptors hD1 and hD2L. 11 Further, the assay can be performed in a 384 well plate format, thus allowing a medium-throughput screening. The Ca 2+ assay distinguishes between agonists and antagonists, and yields information about the potency of an agonist (EC50: effective concentration 50%) or an antagonist (IC 50 : inhibitory concentration 50%, or apparent K value: apparent inhibition constant calculated according to the Cheng-Prusoff equation). 13 For many wellknown ligands, K values obtained by radioligand binding exist in the literature. 5 However, to test whether K values 
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MATERIALS AND METHODS
Cell Culture
Stable transfected human embryonic kidney (HEK293) clonal cell lines were cultured in Dulbecco's modified Eagle Medium Nutrient Mixture F-12 Ham (DMEM/F12 1:1 Mixture) (Sigma Chemical, Taufkirchen, Germany) containing 100 μg/mL streptomycin, 100 U/mL penicillin G, 10% fetal bovine serum (Sigma Chemical), 5mM Lglutamine (Sigma Chemical), and 200 μg/mL G-418 (Calbiochem-Novabiochem Corporation, San Diego, CA). Cells were incubated at 37°C in 5% CO 2 .
Stable Transfection of HEK293 Cells
Stable cell lines of HEK293 cells (ATCC, Rockville, MD) were prepared by transfection of pcDNA3 containing a fragment coding for the entire human dopamine receptor hD1 or hD2L, respectively. Transfection was performed with the Roti-Fect transfection reagent (Roth, Karlsruhe, Germany). The pcDNA3-hD1 vector was obtained by subcloning of the hD1 cDNA from pGEM3-hD1 plasmid into the EcoRI and XbaI sites of pcDNA3 (Invitrogen Corporation, Carlsbad, CA). Clonal selection was performed by adding 400 μg/mL G-418 to the culture medium. The pcDNA3-hD2L vector was obtained from Dr W. Sadée (San Francisco, CA). Expression levels (B max ) and dissociation equilibrium constants (K d 
Measurement of Intracellular Ca2+ in HEK293 Cells
Ca 2+ fluorescence measurements were performed using a NOVOstar microplate reader (BMG LabTechnologies, Offenburg, Germany) equipped with a pipettor and 2 injectors as previously described.
11 HEK293 cells expressing the respective dopamine receptor were harvested with 0.05% trypsin/0.02% EDTA and rinsed with culture medium containing 10% fetal bovine serum, 100 μg/mL streptomycin, 100 U/mL penicillin G, and 1mM Lglutamine. Pelleted cells were then resuspended in fresh medium. They were kept under 5% CO 2 at 37°C for 45 minutes and vortexed every 15 minutes. After 2 washes with Krebs-HEPES buffer, cells were loaded with 3μM Oregon Green 488 BAPTA-1/AM (Molecular Probes, Eugene, OR) for 1 hour at 25°C in the same buffer containing 1% Pluronic F-127. Then, cells were rinsed 3 times with Krebs-HEPES buffer containing 0.5% bovine serum albumin, counted by using a Casy I Model TT cell
Materials
cDNA for hD1 cloned in pGEM3 (Promega, Madison, WI) was obtained from Dr David Grandy (Portland, OR). Compound LE300 was synthesized in the group of Dr Jochen Lehmann (Bonn, Germany), according to Witt et al. 14 All other compounds and reagents were obtained at Sigma Chemical unless otherwise stated.
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(2) counter device (Schaerfe System GmbH, Reutlingen, Germany); diluted; and evenly plated into black 384 well plates with clear bottom (Greiner, Frickenhausen, Germany) at a density of approximately 15 000 cells/well. The volume of cell suspension added to each well was 64 μL. Microplates were kept at 37°C. Fluorescence intensity was measured at 520 nm (bandwidth 35 nm) for 7 seconds at 1.0-second intervals to monitor baseline. After 8 seconds, 8 μL of buffer alone or test compounds (agonists or antagonists) dissolved in buffer were then injected sequentially into separate wells by using the pipettor, and fluorescence intensity was monitored at 520 nm (bandwidth 35 nm) for 22 seconds at 0.4-second intervals. Excitation wavelength was 485 nm (bandwidth 12 nm). After approximately 45 minutes of incubation, 8 μL of a standard agonist in a concentration of ~5x EC50 (100 nM SKF38393 for hD1, and 30 nM quinpirole for hD2L receptors) was injected into the same wells (containing cells and test compounds [agonists or antagonists]), thus allowing estimation of the ability of a test compound to block agonist-induced increase in intracellular Ca 2+ and to calculate an apparent K value.
where IC 50 is the inhibitory concentration 50% of the antagonist LE300 (replacing 50% of bound radioactivity), K d is the dissociation equilibrium constant of the used radioligand, and L is the molar concentration of the used radioligand.
RESULTS
The recently developed functional Ca 2+ assay served as a method of screening at human dopamine receptors.
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A reproducible concentration-dependent Ca 2+ signal, measured as increase in fluorescence upon Ca 2+ binding to Oregon Green 488 BAPTA-1, was observed for agonist stimulation of hD1 and hD2L receptors, respectively ( Figure 1 , Figure 2 ). SKF38393 serves as an example of an agonist at hD1 receptors in Figure 1 , pergolide as agonist for hD2L receptors in Figure 2 . Injection of increasing concentrations of known antagonists of hD1 or hD2L receptors did not change the basal fluorescence levels in either cell line, thus indicating that the observed increase in fluorescence after injection of increasing concentrations of agonist is mediated by receptors rather than mechanical stress ( Figure 1 , Figure 2 ). Further, injection of SKF38393 or pergolide into wildtype HEK293 cells lacking dopamine receptors did not yield any response up to 100μM (data not shown). One critical factor in yielding reproducible agonist concentration response curves turned out to be the method of harvesting the cells used for the Ca 2+ assay. If cells were harvested using trypsin/EDTA and minimum application of mechanical forces (ie, no scraping of cells), dopamine receptor expressing HEK293 cells showed a large increase in fluorescence after injection of agonist, yielding a maximum response after approximately 15 seconds as shown for hD1 receptors stimulated with 100nM SKF38393 ( Figure 3A , filled squares). However, if the same cells were harvested by mechanical scraping using cell scrapers, only a tiny response could be monitored after injection of 100nM SKF38393 ( Figure 3A , open squares), peaking at approximately 3 seconds and completely disappearing within 10 seconds after injection of agonist. The results of the 2 different harvesting methods -ie, the cells -were therefore monitored after fluorescent dye loading with a Casy I Model TT cell counter device estimating the size distribution pattern of cells. As can be seen in representative examples in Figures 3B and 3C , the size distribution pattern changes dramatically if different cell harvesting methods are used. For both experiments, one T75 flask with 90% confluent hD1 expressing HEK293 cells was used, respectively; therefore, both experiments started with the same number of cells. ] ) was calculated as follows 35 :
F max refers to fluorescence intensity measured after permeabilization of the cells with 1% Triton X-100. Then, 10mM EDTA was added to chelate Ca
2+
, and minimum fluorescence intensity was obtained (F min ). An equilibrium dissociation constant (K d ) of 170nM was used for Oregon Green 488 BAPTA-1 (Molecular Probes, Eugene, OR). Intracellular Ca 2+ was estimated for each experiment to control for even loading of fluorescent dye. Quantitative data were obtained by estimating the maximum fluorescence intensity of each data set.
Data Analysis
Concentration response curves were constructed using nonlinear regression curve fit (sigmoidal dose response equation with variable hill slope), which was performed by using Prism software 3.0 from GaphPad. Hill slopes (n H ) were not significantly different from unity. Apparent K values for functional experiments (Ca 2+ assay) were calculated according to the following equation adapted from Cheng and Prusoff 13 :
where IC 50 is the inhibitory concentration 50% of the antagonist, EC 50 is the effective concentration 50% of the used agonist (ie, SKF38393 for hD1, and quinpirole for hD2L receptors), and L is the molar concentration of the used agonist. leaves a majority of shrunk cells (diameter <10 μm) or cell debris (Figure 3C) . Thus, although the same number of cells were used at the start of both harvesting experiments, the outcomes are quite different: whereas harvesting with trypsin/EDTA leaves 2.4 x 10 6 viable cells/mL (diameter range of 10-40 μm), mechanical harvesting with a cell scraper yields only one third that number of viable cells (0.8 x 10 6 cells/mL in the range of 10-40 μm).
Seven agonists of dopamine receptors (hD1 and/or hD2) were tested for agonistic behavior in the Ca 2+ assay by injection into a suspension of hD1 or hD2L receptor expressing cells, respectively, and Ca 2+ mediated changes in fluorescence were monitored. Resulting EC 50 values are listed in Table 3 . All compounds known as potent agonists at hD1 receptors also behaved as agonists in the Ca 2+ assay. Bromocriptine, a compound with weak affinity at the hD1 receptor (K = 440nM 5 ); quinpirole, with very weak affinity at the hD1 receptor (K = 1900 nM 5 ); and mesulergine did not display agonistic activity at the hD1 receptor (EC50 > 10 000 nM). Interestingly, even though pergolide, apomorphine, SKF38393, and lisuride are reported to have similar high-affinity binding at hD1 receptors (K = 0.8, 0.7, 1.0, and 5.6nM for pergolide, apomorphine, SKF38393, and lisuride, respectively 5, 23 ), their EC 50 values differ ( Table 3) : apomorphine is ~4-fold, pergolide~10-fold, and lisuride ~75-fold less potent than SKF38393 at hD1 receptors in the functional Ca 2+ assay. Pergolide, apomorphine, and quinpirole are equipotent agonists in the low nanomolar range at hD2L receptors in the Ca 2+ assay, as listed in Table 3 . However, lisuride and bromocriptine also display nanomolar affinity (K = 0.8 or 0.6nM for lisuride or bromocriptine, respectively 29, 31 ) but are weak agonists in the Ca 2+ assay at hD2L receptors (EC 50 = 175 or 1635nM for lisuride or bromocriptine, respectively, Table 3 ). Mesulergine, described as a weak dopamine receptor agonist, 31, 36 displayed an EC 50 of ~10 000nM at hD2L receptors.
Next, 10 structurally different antagonists of hD1 and/or hD2 receptors were tested ( Table 4) . Upon injection of the antagonists into a hD1 or hD2L receptor expressing cell suspension, no change in baseline fluorescence occurred (eg, displayed for the antagonists haloperidol, SCH23390, and chlorprothixene at hD1 receptors, Figure 1 , and displayed for clozapine, haloperidol, and chlorprothixene at hD2L receptors, Figure 2) . After injection, antagonists were incubated with the receptor expressing cells for 45 minutes to allow equilibration. Then, in a second injection, a standard agonist (in a concentration of ~5-fold EC 50 , ie, 100nM SKF38393 for hD1 receptors, or 30nM quinpirole for hD2L receptors) was injected into the cell suspension preincubated with antagonists, and fluorescence was monitored. Thus, apparent K values for antagonists were obtained. However, the same procedure -injection of test compound, 45 minutes of equilibration, and subsequent injection of a standard agonist (SKF38393 or quinpirole for hD1 or hD2L receptors, respectively) -was applied for the agonist compounds in Table 3 , therefore also yielding "apparent K values" as listed in the agonist portion of Figures 4A and 4B) . If available, binding data were taken from human dopamine receptors. Otherwise, data were taken from rat, calf, or dog striatal receptors (Tables 1 and 2) . Literature was searched to get an overview of the range of literature-based binding data, and lowest and highest found K values were listed (Tables 1 and 2 ). For agonists, K values for the highand low-affinity binding sites are listed, respectively. For D1 receptors, literature-based K values are in a slightly narrower range (maximum 19.5-fold difference for SCH23390, Table 1 ) than literature-based K values for D2 receptors (27.4-fold difference for K values for haloperidol, 21.2-fold difference for chlorpromazine, 11-fold difference for clozapine, Table 2 ). Not surprisingly, there are big differences between high-and low-affinity binding sites for agonists at both D1 and D2 receptors (the agonist portions of Tables 1 and 2 ). LE300, a novel dopamine receptor antagonist, was included in this study because it contains a novel chemical structure for dopamine receptor antagonists (benz[d]indolo[2,3-g]azecine ring system) and has recently been described as a dopamine receptor antagonist.
14 The purpose of this study was to test whether the functional Ca Tables 1 and 2 ). The overall correlation for D1 receptors yielded an r 2 of 0.7796, showing a significant correlation with P < .0001 ( Figure 4A) . The slope is not significantly different from 1 (95% confidence interval is between 0.72 and 1.24). For D2 receptors, the overall correlation gave an r 2 of 0.7743 (significant correlation with P < .0001 [ Figure 4B] ). In contrast to D1 receptors, the slope for D2 receptor correlation is significantly different from 1 (95% confidence interval is between 0.51 and 0.85). These data suggest that apparent functional and radioligand binding K values are significantly correlated but that an increase in radioligand binding yields a smaller increase in functional effects (measured as Ca D2 receptors (B) , respectively. K i of LE300 was estimated as previously described [11] . Apparent functional K i values were obtained by measuring the inhibition of agonist (100nM SKF38393 at D1, 30nM quinpirole at D2 receptors) induced increase in intracellular Ca 2+ after preincubation with the respective test compound. For agonists, only literature K i values for the high-affinity receptor state were used. For antagonists, minimum and maximum K i values found in the literature (see Tables 1 and 2) were used for correlation with apparent functional K i values. r 2 was calculated as 0.7796 for D1 (A) and as 0.7743 for D2 receptors (B). For both receptors, a significant correlation (P<.0001) was obtained.
DISCUSSION
Screening of compounds at GPCRs is an important issue not only in high-throughput screening laboratories but also in situations where fewer compounds need to be tested. Besides the affinity of a compound, functional properties are important. Further, it is desirable for one assay to be able to be applied to as many GPCRs as possible. Recently, a functional assay based on the change in intracellular Ca 2+ upon agonist stimulation was described for differently coupled GPCRs (G s , G, Gq). 11 In this report, it was shown that compounds described in the literature as agonists at D1 and/or D2 receptors are indeed capable of inducing a Ca 2+ signal ( Table 3 ). The specificity of this signal was proved by antagonist injection, which did not yield a Ca 2+ response (Figure 1 ,  Figure 2) , and by injection of agonists into control cells lacking dopamine receptor expression (HEK293 wildtype cells, data not shown). Harvesting the dopamine receptor expressing HEK293 cells for the functional Ca 2+ assay needs to be done carefully: cells must be harvested gently (by use of trypsin/EDTA and as little mechanical force as possible) to retain a maximum sensitivity ( Figure 3A) . The Ca 2+ assay was performed with dopamine receptor expressing cells in suspension rather than attached cells because of the lack of a microplate washer. However, if a microplate washer is available, the Ca 2+ assay may be performed with attached cells, too.
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Known dopamine receptor antagonists from various chemical classes are capable of blocking the agonist response in a concentration-dependent manner in hD1 or hD2L receptor expressing cells, resulting in a list of apparent functional K values (Table 4) . Thus, the Ca 2+ assay reveals not only whether a test compound is a dopamine receptor ligand (apparent K value) but also whether it is an agonist or an antagonist. The functional potency of agonists in the Ca 2+ assay (ie, the EC 50 values, Table 3 ) does not correlate with binding data in the literature (Tables 1 and 2) . However, all literature-known hD1 or hD2 agonists showed an agonistic response in the Ca 2+ assay ( Table 3 ). There may be various reasons for differences between functional EC 50 values and radioligand binding data (K values), as seen, for instance, for pergolide at the D1 receptor (highaffinity radioligand binding K = 0.80 nM, 5 low-affinity radioligand binding K = 1363 nM, 16 functional EC 50 in the Ca 2+ assay: 171nM, Table 3 ). First, dopamine receptors are known to exist in 2 different states: a high-and a low-affinity state for agonists. 5, 37 Especially in recombinant cell lines, the amount of available G-proteins for receptor coupling is limited, thus leading to a relevant number of uncoupled receptors in a low-affinity state. 5 Further, different agonists may stabilize different conformations of the receptor with different abilities to couple to and activate G-proteins. 38 Second, Ca 2+ is a very fast signal peaking after ~15 seconds, thus not allowing equilibration of the agonist with the receptor. This may lead to an incomplete monitoring of an agonist's potency when applying the functional Ca 2+ assay. Third, since Ca 2+ is a "third" messenger for G s and G coupled receptors like hD1 and hD2L, a far downstream -but nevertheless universally applicable -signal is monitored. Different agonists may activate the Ca 2+ pathway with different potency by inducing different receptor conformations. 38 Taken together, agonists may display different behavior in equilibrium radioligand displacement studies and in functional experiments like the Ca 2+ assay. However, all potent literature-known agonists have been successfully identified with the Ca 2+ assay as agonists ( Table 3) . 2002; 4 (4) article 31 (http://www.aapspharmsci.org) . Table 3 . EC 50 Values and SD (nM) of Known Dopamine Receptor Agonists at hD1 and hD2L Receptor Expressing HEK293 Cells* Table 4 . Apparent K i Values and SD (nM) of Dopamine Receptor Antagonists and Agonists at hD1 and hD2L Receptor Expressing HEK293 Cells* For the purpose of quantifying the effects of agonists by functional screening, the estimation of apparent functional K values (performed as described under "Materials and Methods") is better suited, as can be seen by comparison of apparent functional K values with high-affinity binding data (the agonist portions of Tables 1 and 2 , "K (nM) Ca 2+ Assay" compared with "K (nM) Binding"). Apparent functional K values of agonists are a measure for the dose-dependent functional blockage of dopamine receptors after continuous (45 minutes) preincubation with such agonistic test compounds. During the 45-minute preincubation with agonistic test compounds, dopamine receptors are first activated (which was not measured), and then as a consequence of continuous stimulation, as literature data suggest, desensitized and/or internalized. [39] [40] [41] After 45-minute incubation with agonistic test compounds, 100 nM SKF38393 for D1 or 30nM quinpirole for D2 receptors was injected. All agonistic test compounds were able to functionally block D1 or D2 receptors in a dose-dependent manner (the agonist portions of Tables 1 and 2 ). Further, apparent K values calculated from the Ca 2+ assay correlate well with literaturebased high-affinity binding data (the agonist portions of Tables 1 and 2) . Mesulergine, a weak dopamine receptor agonist, 36, 42 was inactive at hD1 receptors and a very weak agonist at hD2L receptors in the Ca 2+ assay (EC 50~1 0 000 nM). However, no radioligand binding data for mesulergine at dopamine receptors were found in the literature. Mesulergine is a potent antagonist at various serotonin receptors, especially the 5-HT2C receptor. 43 Amantadine is used as a drug in the treatment of Parkinson's disease even though its efficacy is poor compared to L-dopa's. 44 Although the exact mechanism of action of amantadine against Parkinson's disease is still unknown, amantadine increases the dopaminergic tone without directly stimulating dopamine receptors. 45 In the Ca 2+ assay, amantadine did not show agonistic activity at dopamine receptors, but, interestingly, amantadine inhibits the hD2L receptor with a K of 53.5nM (Table 4) . These data, suggesting that amantadine is a moderate D2 antagonist, are interesting considering the fact that repeated treat- 2002; 4 (4) article 31 (http://www.aapspharmsci.org) . ment with amantadine induces a moderate increase in [11C]-raclopride binding, indicating an increase of D2 receptors in patients with Parkinson's disease. 45 Finally, the overall correlation between apparent functional (Ca 2+ assay) and radioligand binding (literature) K values is quite good ( Figure 4A, 4B ). There is a significant correlation of apparent functional and binding K values at D1 and D2 receptors (P<.0001), yielding r 2 values of 0.7796 and 0.7743, respectively. However, for some compounds there is a discrepancy between apparent functional and binding K values of up to 10-fold: fluphenazine at D2 receptors does not fit into the rank order of potency ( Table 2 ). The apparent functional K value is~10-fold too high. However, it is the only compound at D2 receptors that does not fit into the rank order of potency. At D1 receptors, apparent functional K values are generally higher than their corresponding literature-based radioligand binding K values ( Table 1) . Only chlorpromazine and lisuride do not fit into the rank order of potency (measured as apparent functional K). However, the deviation in the rank order of potency is small for chlorpromazine, and radioligand binding K values for lisuride were measured at calf or dog striatum, thus possibly adding to the difference between functional and binding data. When comparing apparent functional with binding K values, one also has to take into account that apparent K values depend on the expression level of the respective receptor. Thus, the expression level of D1 and D2 receptors together with the used agonist concentration in the Ca 2+ assay will influence the apparent functional K and lead to different values than binding K's. This -at first view -limitation of the functional Ca 2+ assay is no problem if test compounds are measured together with known (standard) ligands under exactly the same experimental conditions, and the rank order of potency of all compounds is subsequently compared. Looking at the rank order of potency, only 1 or 2 compounds out of 17 at the D2 or the D1 receptor did not fit into the rank order (Tables 1 and 2) . Further, it needs to be taken into account that radioligand binding data in the literature are not too consistent. For haloperidol, for instance, K values between 0.35 and 9.6 nM were found for D2 receptors. 25, 26 Some of these variations may be explained by different experimental setups: not all radioligand binding K values in the literature were obtained at human receptors (Tables 1 and 2) . Further, some experiments were performed with recombinantly expressed receptors, some with native tissue (Tables 1 and 2, "Binding K Literature"). Another issue is that radioligand binding experiments are performed in equilibrium. In the Ca 2+ assay, the antagonist is allowed to equilibrate with the receptor, but subsequent injection of agonist induces a fast signal (peaking within ~15 seconds, Figure 3A ) not allowing equilibrium between antagonist, agonist, and receptor, and thus -depending on the dissociation rate constant of the antagonistleading to decreased or increased apparent functional K values. Apparent functional K values obtained with the Ca 2+ assay are also in accordance with functional data in the literature measured by [ 35 S]GTPgS binding. 46 Gilliland and Alper found the same rank order of potency for agonists and antagonists at D2 receptors as is presented in Table  2 in apparent functional K values (agonists: pergolide>apomorphine>quinpirole; antagonists: spiperone>haloperidol>clozapine). In conclusion, considering the differences in experimental setups (buffers, source of receptors, equilibrium or nonequilibrium conditions), the overall correlation between apparent functional K values obtained by the Ca 2+ assay and literature-based radioligand binding K values is significant for D1 and D2 receptors (Figure 4) . Further, the rank order of potency remains the same for both functional and radioligand binding data with few exceptions (Tables 1 and 2) . Taken together, these results suggest that screening of potential ligands at dopamine receptors with the simple, medium-throughput functional Ca 2+ assay as recently described 11 may allow the replacement of radioligand binding experiments, and additionally yield information about agonistic or antagonistic behavior of a compound.
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